See more : KWG Resources Inc. (KWG.CN) Income Statement Analysis – Financial Results
Complete financial analysis of Reviva Pharmaceuticals Holdings, Inc. (RVPH) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Reviva Pharmaceuticals Holdings, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Frontier Lithium Inc. (FL.V) Income Statement Analysis – Financial Results
- Globe Industries Corporation (1324.TW) Income Statement Analysis – Financial Results
- Hongkong Land Holdings Limited (HKLB.L) Income Statement Analysis – Financial Results
- Bioservo Technologies AB (publ) (BIOS.ST) Income Statement Analysis – Financial Results
- MECOM Power and Construction Limited (1183.HK) Income Statement Analysis – Financial Results
Reviva Pharmaceuticals Holdings, Inc. (RVPH)
About Reviva Pharmaceuticals Holdings, Inc.
Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is RP5063, which is in Phase III clinical trials for the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. It is also developing RP1208 that is in pre-clinical development studies for the treatment of depression and obesity. The company is headquartered in Cupertino, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 724.74K | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | -724.74K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 31,419.82B | 18.95M | 4.85M | 295.15K | 195.74K | 946.30K |
| General & Administrative | 8,083.82B | 5.36M | 5.25M | 2.14M | 181.12K | 175.58K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 8,083.82B | 5.36M | 5.25M | 2.14M | 181.12K | 175.58K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 39,503.64B | 24.31M | 10.10M | 2.43M | 376.86K | 1.12M |
| Cost & Expenses | 39.50M | 24.31M | 10.10M | 2.43M | 376.86K | 1.12M |
| Interest Income | 0.00 | 182.80K | 0.00 | 105.18K | 201.00 | 0.00 |
| Interest Expense | 0.00 | 182.80K | 2.41K | 1.45M | 469.37K | 0.00 |
| Depreciation & Amortization | 0.00 | 194.71K | 236.56K | 105.77K | 846.00 | 1.02K |
| EBITDA | -39,503.64B | -24.11M | -10.10M | -2.33M | -376.01K | -1.12M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -39,503.64B | -24.31M | -10.10M | -2.43M | -376.86K | -1.12M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 39,503.60B | -11.91K | 1.59M | -1.35M | -469.17K | -557.68K |
| Income Before Tax | -39.24M | -24.32M | -8.52M | -3.78M | -846.03K | -1.68M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -16.95B | 20.78K | 6.00K | 800.00 | 800.00 | 800.00 |
| Net Income | -39,260.84B | -24.34M | -8.52M | -3.78M | -846.83K | -1.68M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.65 | -1.25 | -0.58 | -1.24 | -0.31 | 0.00 |
| EPS Diluted | -1.65 | -1.25 | -0.58 | -1.24 | -0.31 | 0.00 |
| Weighted Avg Shares Out | 23.80M | 19.52M | 14.79M | 3.06M | 2.77M | 0.00 |
| Weighted Avg Shares Out (Dil) | 23.80M | 19.52M | 14.79M | 3.06M | 2.77M | 0.00 |
Reviva Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
CUPERTINO, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPH
NEW YORK , May 23, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Reviva Pharmaceuticals Holdings, Inc. ("Reviva" or the "Company") (NASDAQ: RVPH). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Reviva to Participate in the BIO International Convention
CUPERTINO, Calif., May 21, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPH
NEW YORK , May 16, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Reviva Pharmaceuticals Holdings, Inc. ("Reviva" or the "Company") (NASDAQ: RVPH). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980,...
Reviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia
– 358 enrolled and 223 patients currently on treatment across sites in the USA, Europe and Asia – – Brilaroxazine is generally well tolerated to date in patients with acute and stable schizophrenia – – Topline data from 1-year open-label extension...
Reviva Reports First Quarter 2024 Financial Results and Recent Business Highlights
– Gained alignment with U.S. Food and Drug Administration (FDA) on brilaroxazine clinical trials for New Drug Application (NDA) submission in schizophrenia –
Reviva to Present New Preclinical Efficacy Data on Brilaroxazine in Idiopathic Pulmonary Fibrosis at 2024 ATS International Conference
CUPERTINO, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory...
RVPH INVESTOR NOTICE: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Reviva Pharmaceuticals Holdings, Inc. Investors to Inquire About Securities Class Action Investigation - RVPH
NEW YORK , May 10, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) resulting from allegations that...
Reviva to Present New Non-Clinical Pharmacology Data on Brilaroxazine at the ASPET 2024 Annual Meeting
CUPERTINO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPH
NEW YORK , May 6, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Reviva Pharmaceuticals Holdings, Inc. ("Reviva" or the "Company") (NASDAQ: RVPH). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Source: https://incomestatements.info
Category: Stock Reports